Heteroaryl inhibitors of PDE4
AssigneeTetra Discovery Partners, LLC
InventorsMark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
Claims14
A method of treating or reducing a symptom of a PDE4-mediated disease chosen from depression, anxiety, degradation of learning and memory ability, Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease, late motor disorders, mild cognitive impairment, stroke, ischemia, depression secondary to illness, major depressive disorder, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, transverse myelitis, amyotrophic lateral sclerosis, and arteriosclerotic dementia, comprising orally administrating to a patient in need thereof twice daily an oral pharmaceutical composition comprising between 10 mg to 200 mg of a compound having the structural formula
- and/or a pharmaceutically acceptable salt thereof.
A method of enhancing memory and cognition in a patient with a PDE4-mediated disease, comprising orally administrating to a patient in need thereof twice daily an oral pharmaceutical composition comprising between 10 mg to 200 mg of a compound having the structural formula
- and/or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.